CB2 Receptor Agonist Therapy for IgE Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively reduce serum levels of immunoglobulin E (IgE) in subjects, which contributes to allergic reactions and related symptoms, as they do not adequately modulate immune responses through CB2 cannabinoid receptors.
Innovation Solution
Administering a pharmaceutical composition comprising an agonist of the CB2 cannabinoid receptor, such as 1-(2′,4′-Dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, to reduce IgE levels by activating CB2 receptors, thereby mitigating allergic responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to modulate immune responses, then immune function is maintained, but serum IgE levels are not effectively reduced
Solution Approach 1:
The patent changes the pharmacological parameter by introducing CB2 receptor agonists that specifically target the cannabinoid 2 receptor pathway. This parameter change (activating CB2 receptors) leads to a different immune modulation profile that reduces IgE production while maintaining other immune functions, thereby resolving the contradiction between maintaining immune function and reducing IgE levels.
2Quantity of substance
If CB2 receptor agonists are administered, then serum IgE levels are reduced, but potential side effects on other immune functions may occur
Solution Approach 1:
The CB2 receptor agonist acts as an intermediary substance that selectively modulates the immune system through the CB2 receptor pathway. This intermediary approach allows for specific reduction of IgE production while sparing other immune functions that are regulated through different pathways, thus reducing harmful side effects while achieving the desired therapeutic effect.
Data Source
AI summary
The present disclosure provides methods and pharmaceutical compositions for reducing the serum level of immunoglobulin IgE in an animal or human subject. It has been found that reducing or inhibiting the activity of the cannabinoid receptor CB2 leads to an increase in IgE in serum levels. Conversely, activation of the CB2 receptor by an agonist results in a reduction in IgE serum levels. The compositions and methods of the disclosure, therefore, provide a means to reduce or eliminate symptoms of immune system-related conditions resulting from IgE generation, such as an allergy, hay fever, and the like.